DARE DARE BIOSCIENCE INC Operational Disruptions 8-K Filing 2023 - Clinical Study Results Dar Bioscience, Inc. issued a press release regarding the results of its Phase 1/2 clinical study of DARE-HRT1, an investigational hormone therapy for menopausal symptoms, and plans to advance it into a Phase 3 trial.Get access to all SEC 8-K filings of the DARE BIOSCIENCE INC